120 related articles for article (PubMed ID: 16609358)
1. Novel preparation and characterization of a trastuzumab-streptavidin conjugate for pre-targeted radionuclide therapy.
Hainsworth JE; Harrison P; Mather SJ
Nucl Med Commun; 2006 May; 27(5):461-71. PubMed ID: 16609358
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
Sato N; Hassan R; Axworthy DB; Wong KJ; Yu S; Theodore LJ; Lin Y; Park L; Brechbiel MW; Pastan I; Paik CH; Carrasquillo JA
J Nucl Med; 2005 Jul; 46(7):1201-9. PubMed ID: 16000290
[TBL] [Abstract][Full Text] [Related]
3. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
4. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Foulon CF; Bigner DD; Zalutsky MR
Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, and biological evaluation of a streptavidin-chimeric t84.66 conjugate for antibody pretargeting.
Jia F; Shelton TD; Lewis MR
Cancer Biother Radiopharm; 2007 Oct; 22(5):654-64. PubMed ID: 17979568
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
[TBL] [Abstract][Full Text] [Related]
8. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
[TBL] [Abstract][Full Text] [Related]
9. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Rasaneh S; Rajabi H; Babaei MH; Daha FJ
Nucl Med Biol; 2010 Nov; 37(8):949-55. PubMed ID: 21055626
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
Urbano N; Papi S; Ginanneschi M; De Santis R; Pace S; Lindstedt R; Ferrari L; Choi S; Paganelli G; Chinol M
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):68-77. PubMed ID: 16755333
[TBL] [Abstract][Full Text] [Related]
11. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
Persson M; Tolmachev V; Andersson K; Gedda L; Sandström M; Carlsson J
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1457-62. PubMed ID: 16193312
[TBL] [Abstract][Full Text] [Related]
12. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.
Talanov VS; Yordanov AT; Garmestani K; Milenic DE; Arora HC; Plascjak PS; Eckelman WC; Waldmann TA; Brechbiel MW
Nucl Med Biol; 2004 Nov; 31(8):1061-71. PubMed ID: 15607488
[TBL] [Abstract][Full Text] [Related]
14. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
[TBL] [Abstract][Full Text] [Related]
15. Purification of cyclotron-produced 203Pb for labeling Herceptin.
Garmestani K; Milenic DE; Brady ED; Plascjak PS; Brechbiel MW
Nucl Med Biol; 2005 Apr; 32(3):301-5. PubMed ID: 15820766
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
[TBL] [Abstract][Full Text] [Related]
18. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.
Choi J; Vaidyanathan G; Koumarianou E; McDougald D; Pruszynski M; Osada T; Lahoutte T; Lyerly HK; Zalutsky MR
Nucl Med Biol; 2014; 41(10):802-12. PubMed ID: 25156548
[TBL] [Abstract][Full Text] [Related]
19. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
20. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
